AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

PARADIGM BIOPHARMACEUTICALS

0.250

+0.0104.17%

Volume:736.99K

Turnover:184.41K

Market Cap:151.71M

PE:-1.64

High:0.255

Open:0.250

Low:0.245

Close:0.240

52wk High:0.470

52wk Low:0.135

Shares:606.85M

Float Shares:353.07M

Volume Ratio:1.85

T/O Rate:0.21%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.152

EPS(LYR):-0.152

ROE:-456.96%

ROA:-138.75%

PB:43.71

PE(LYR):-1.64

Loading ...

Overview Company News Filings

Paradigm Biopharmaceuticals Partners With UK University for Osteoarthritis Research; Shares Down 4%

MT Newswires Live

Paradigm Biopharmaceuticals Hits 50% Enrollment in Phase 3 Osteoarthritis Trial; Shares Up 4%

MT Newswires Live

Paradigm Biopharmaceuticals Activates Additional Hong Kong Site For Global Phase Three Knee Osteoarthiritis Study

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/PAR.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PAR.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PAR.AU\",,,,,undefined,":{"symbol":"PAR.AU","market":"AU","secType":"STK","nameCN":"PARADIGM BIOPHARMACEUTICALS","latestPrice":0.25,"timestamp":1789345839801,"preClose":0.24,"halted":0,"volume":736993,"delay":0,"changeRate":0.041666666666666706,"nameEN":"PARADIGM BIOPHARMACEUTICALS","floatShares":353065639,"shares":606848701,"eps":-0.152232,"marketStatus":"Trading","change":0.01,"latestTime":"09-14 10:32:21 AEST","open":0.25,"high":0.255,"low":0.245,"amount":184407,"amplitude":0.041667,"askPrice":0.25,"askSize":66802,"bidPrice":0.245,"bidSize":171663,"shortable":3,"etf":0,"ttmEps":-0.152232,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789365600000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.24,"openAndCloseTimeList":[[1789344000000,1789365600000]],"volumeRatio":1.845664,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"PAR.AU","preClose":0.24,"auctionPrice":0.25,"auctionVolume":222850,"auctionTime":1789343943669,"referenceTime":1789122603091,"auction":1,"marketStatus":"盘前竞价","timestamp":1789343943669}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PAR.AU\",,,,,undefined,":{"symbol":"PAR.AU","floatShares":353065639,"roa":"-138.75%","roe":"-456.96%","lyrEps":-0.152232,"volumeRatio":1.845664,"shares":606848701,"dividePrice":0,"high":0.255,"amplitude":0.041667,"preClose":0.24,"low":0.245,"week52Low":0.135,"pbRate":"43.71","psRate":"17954.10","week52High":0.47,"institutionHeld":0,"latestPrice":0.25,"committee":0.439733,"eps":-0.152232,"divideRate":0,"volume":736993,"delay":0,"ttmEps":-0.152232,"open":0.25,"prevYearClose":0.34,"prevWeekClose":0.24,"prevMonthClose":0.225,"prevQuarterClose":0.165,"fiveDayClose":0.275,"twentyDayClose":0.175,"sixtyDayClose":0.17,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PAR.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2025-02-06","symbol":"PAR.AU","defaultRemindTime":1738796400000,"type":"split","dateTimestamp":1738760400000,"forFactor":4,"toFactor":5,"ratio":0.8},{"market":"AU","date":"2022-08-17","symbol":"PAR.AU","defaultRemindTime":1660694400000,"type":"split","dateTimestamp":1660658400000,"forFactor":992772,"toFactor":1000000,"ratio":0.992772}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PAR.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PAR.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2624967523","title":"Paradigm Biopharmaceuticals Partners With UK University for Osteoarthritis Research; Shares Down 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624967523","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624967523?lang=en_us&edition=fundamental","pubTime":"2026-04-02 08:34","pubTimestamp":1775090076,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  partnered with City St George's, University of London, UK, to assess the effects of pentosan polysulfate sodium on bone marrow lesions in osteoarthritis, according to a Thursday filing with the Australian bourse.Pentosan polysulfate sodium is the company's investigational therapy under evaluation in phase three clinical development for knee osteoarthritis, the filing said.The research collaboration is expected to run for about 12 months, per the filing.Paradigm Biopharmaceuticals shares fell 4% in morning trade on Thursday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PAR.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623320295","title":"Paradigm Biopharmaceuticals Hits 50% Enrollment in Phase 3 Osteoarthritis Trial; Shares Up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623320295","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623320295?lang=en_us&edition=fundamental","pubTime":"2026-03-31 08:02","pubTimestamp":1774915376,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  achieved 50% enrollment in a phase 3 clinical trial of injectable pentosan polysulfate sodium for the potential treatment of osteoarthritis, according to a Tuesday filing with the Australian bourse.The company said it has started dosing of the final participants required for inclusion in the interim analysis, with those results expected in August.The study's primary endpoint is the change in weekly average of daily pain at day 112, while secondary endpoints include improvements in physical function, imaging-based structural outcomes, and safety assessments.The company's shares gained nearly 4% in recent Tuesday trading.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PAR.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620203940","title":"Paradigm Biopharmaceuticals Activates Additional Hong Kong Site For Global Phase Three Knee Osteoarthiritis Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2620203940","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620203940?lang=en_us&edition=fundamental","pubTime":"2026-03-20 09:29","pubTimestamp":1773970163,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  said an additional international clinical trial site in Hong Kong, the Hong Kong Center for Clinical Research, for its global phase three clinical study evaluating injectable pentosan polysulfate sodium in patients with knee osteoarthritis was activated, according to a Friday Australian bourse filing.The site started screening patients, with the study designed to enrol 466 participants globally.Three clinical trial sites in Moldova are expected to be activated in the coming weeks.Its shares rose 2% in recent trading on Friday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PAR.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":23,"code":"91000000","status":"200"}]}}